Skip to main content
European Commission logo print header

Corona Accelerated R&D in Europe

Descripción del proyecto

Consorcio europeo de prevención del coronavirus, inmunoterapia y descubrimiento de fármacos

La pandemia de coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2) constituye la amenaza sanitaria más importante de este siglo. El proyecto financiado con fondos europeos CARE es una coalición de 37 instituciones académicas, empresas farmacéuticas y organizaciones de investigación sin ánimo de lucro. Los principales objetivos del consorcio son desarrollar productos terapéuticos para responder a la emergencia causada por la pandemia actual de SARS-CoV-2 mediante el reposicionamiento de fármacos, así como hacer frente a brotes futuros mediante el descubrimiento de fármacos y de anticuerpos neutralizadores del virus. La potencia y la seguridad de los candidatos a fármacos terapéuticos se evaluarán «in vivo» y en modelos animales. Por otra parte, se generarán anticuerpos monoclonales neutralizadores de virus y se identificarán marcadores inmunitarios. Los compuestos principales finales pasarán a estudios clínicos de fase I y II en humanos.

Objetivo

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situation Report of March 28th 2020, 571,659 patients were diagnosed with Coronavirus Disease 2019 (COVID-19) and 26,493 deaths were reported globally. The wide spectrum of clinical symptoms, disease severity in high risk individuals, transmission efficiency and high mortality, raises an immediate need for vaccines or therapeutics. Given that the viral variant is new in the human population and emerged less than 4 months ago, there is no vaccine or approved therapies. The Corona Accelerated R&D in Europe (CARE) consortium is a coalition of 37 globally renowned academic institutions, pharmaceutical companies and non-profit research organizations who have committed to rapidly and efficiently address this emergent health threat, and the main objectives are: the development of therapeutics (i) to provide an emergency response towards the current COVID-19 pandemic by drug repositioning and (ii) to address the current and/or future coronavirus outbreaks by broad-spectrum small-molecule drug discovery and/or virus-neutralizing antibody discovery. To achieve this, a collection of repurposed drugs, focused libraries and small molecule libraries will be screened against SARS-CoV-2, other emerging SARS-CoV-2 clades and related coronavirus genera in phenotypic or target-based assays. A focused medicinal chemistry campaign will identify small-molecule hits, and Absorption, Distribution, Metabolism and Excretion (ADME), pharmacokinetic/pharmacodynamic (PK/PD), potency and safety of these therapeutic candidates will be assessed in vitro and in animal models. Virus-neutralizing monoclonal antibodies will be generated and further characterized. Immune markers will be identified contributing to the host immune responses to SARS-CoV-2 infections, and the correlation with clinical and virological outcomes will be determined. Finally, lead candidates will be advanced into Phase1 and Phase 2 clinical trials in humans. With this reactive response, the CARE consortium is dedicated to win the fight against coronavirus.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Aportación neta de la UEn
€ 6 630 753,05
Dirección
RUE DE TOLBIAC 101
75654 Paris
Francia

Ver en el mapa

Región
Ile-de-France Ile-de-France Paris
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 8 084 160,05

Participantes (42)